- Home
- DOMH vs AYTU Comparison
DOMH vs AYTU Comparison
Compare DOMH & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- AYTU
- Stock Information
- Founded
- DOMH 1967
- AYTU N/A
- Country
- DOMH United States
- AYTU United States
- Employees
- DOMH N/A
- AYTU N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- AYTU Health Care
- Exchange
- DOMH Nasdaq
- AYTU Nasdaq
- Market Cap
- DOMH 12.1M
- AYTU 9.8M
- IPO Year
- DOMH N/A
- AYTU N/A
- Fundamental
- Price
- DOMH $1.26
- AYTU $1.38
- Analyst Decision
- DOMH
- AYTU
- Analyst Count
- DOMH 0
- AYTU 0
- Target Price
- DOMH N/A
- AYTU N/A
- AVG Volume (30 Days)
- DOMH 12.6K
- AYTU 37.2K
- Earning Date
- DOMH 11-08-2024
- AYTU 02-12-2025
- Dividend Yield
- DOMH N/A
- AYTU N/A
- EPS Growth
- DOMH N/A
- AYTU N/A
- EPS
- DOMH N/A
- AYTU N/A
- Revenue
- DOMH $12,589,000.00
- AYTU $79,759,000.00
- Revenue This Year
- DOMH N/A
- AYTU N/A
- Revenue Next Year
- DOMH N/A
- AYTU N/A
- P/E Ratio
- DOMH N/A
- AYTU N/A
- Revenue Growth
- DOMH 1117.50
- AYTU N/A
- 52 Week Low
- DOMH $1.24
- AYTU $1.30
- 52 Week High
- DOMH $3.20
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- DOMH 25.29
- AYTU 33.90
- Support Level
- DOMH $1.66
- AYTU $1.30
- Resistance Level
- DOMH $1.72
- AYTU $1.47
- Average True Range (ATR)
- DOMH 0.09
- AYTU 0.12
- MACD
- DOMH -0.04
- AYTU -0.01
- Stochastic Oscillator
- DOMH 3.70
- AYTU 17.78
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc is a biotechnology company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The company's oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.